Autolus Therapeutics Stock Performance
AUTL Stock | USD 6.38 0.14 2.24% |
The firm shows a Beta (market volatility) of 0.57, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Autolus Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Autolus Therapeutics is expected to be smaller as well. Autolus Therapeutics has an expected return of -0.0335%. Please make sure to confirm Autolus Therapeutics value at risk, as well as the relationship between the skewness and day median price , to decide if Autolus Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Low | High |
Very Weak
Over the last 90 days Autolus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent basic indicators, Autolus Therapeutics is not utilizing all of its potentials. The recent stock price mess, may contribute to short-term losses for the institutional investors. ...more
Actual Historical Performance (%)
One Day Return 2.24 | Five Day Return 2.9 | Year To Date Return (6.73) | Ten Year Return (74.48) | All Time Return (74.48) |
1 | Brokerages Set Autolus Therapeutics plc PT at 7.83 | 01/30/2024 |
2 | Autolus Announces Pricing of Underwritten Offering | 02/08/2024 |
3 | Strength Seen in Autolus Therapeutics PLC Sponsored ADR Can Its 6.3 percent Jump Turn into More Strength | 02/12/2024 |
4 | Institutional investors in Autolus Therapeutics plc see US137m decrease in market cap last week, although long-term gains have benefitted them. | 02/21/2024 |
5 | Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024 | 02/29/2024 |
6 | Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency certification for Nucleus commercial manufacturing site | 03/12/2024 |
7 | Autolus Therapeutics GAAP EPS of -1.20 misses by 0.10, revenue of 1.69M misses by 0.01M | 03/14/2024 |
8 | Truist Financial Raises Autolus Therapeutics Price Target to 10.00 - Defense World | 03/19/2024 |
9 | Autolus Therapeutics plc Shares Sold by B. Riley Wealth Advisors Inc. - Defense World | 03/26/2024 |
Begin Period Cash Flow | 382.8 M |
Autolus |
Autolus Therapeutics Relative Risk vs. Return Landscape
If you would invest 684.00 in Autolus Therapeutics on December 30, 2023 and sell it today you would lose (46.00) from holding Autolus Therapeutics or give up 6.73% of portfolio value over 90 days. Autolus Therapeutics is currently does not generate positive expected returns and assumes 4.0461% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Autolus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Autolus Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Autolus Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Autolus Therapeutics, and traders can use it to determine the average amount a Autolus Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0083
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | AUTL |
Estimated Market Risk
4.05 actual daily | 35 65% of assets are more volatile |
Expected Return
-0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Autolus Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Autolus Therapeutics by adding Autolus Therapeutics to a well-diversified portfolio.
Autolus Therapeutics Fundamentals Growth
Autolus Stock prices reflect investors' perceptions of the future prospects and financial health of Autolus Therapeutics, and Autolus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Autolus Stock performance.
Return On Equity | -1.02 | ||||
Return On Asset | -0.25 | ||||
Current Valuation | 1.47 B | ||||
Shares Outstanding | 265.93 M | ||||
Price To Earning | (19.33) X | ||||
Price To Book | 14.89 X | ||||
Price To Sales | 977.25 X | ||||
Revenue | 1.7 M | ||||
Gross Profit | (130.86 M) | ||||
EBITDA | (188.46 M) | ||||
Net Income | (208.38 M) | ||||
Cash Per Share | 2.38 X | ||||
Debt To Equity | 0.08 % | ||||
Current Ratio | 7.29 X | ||||
Cash Flow From Operations | (145.59 M) | ||||
Earnings Per Share | (1.20) X | ||||
Total Asset | 375.38 M | ||||
Retained Earnings | (878.56 M) | ||||
Current Asset | 102.22 M | ||||
About Autolus Therapeutics Performance
To evaluate Autolus Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Autolus Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Autolus Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Autolus Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Autolus's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for 2024 | ||
Return On Capital Employed | (0.59) | (0.62) | |
Return On Assets | (0.56) | (0.58) | |
Return On Equity | (1.87) | (1.78) |
Things to note about Autolus Therapeutics performance evaluation
Checking the ongoing alerts about Autolus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Autolus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Autolus Therapeutics generated a negative expected return over the last 90 days | |
Autolus Therapeutics has high historical volatility and very poor performance | |
The company reported the previous year's revenue of 1.7 M. Net Loss for the year was (208.38 M) with loss before overhead, payroll, taxes, and interest of (130.86 M). | |
Autolus Therapeutics currently holds about 216.44 M in cash with (145.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38. | |
Autolus Therapeutics has a frail financial position based on the latest SEC disclosures | |
Roughly 18.0% of the company shares are held by company insiders | |
Latest headline from news.google.com: Autolus Therapeutics plc Shares Sold by B. Riley Wealth Advisors Inc. - Defense World |
- Analyzing Autolus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Autolus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Autolus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Autolus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Autolus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Autolus Therapeutics' stock. These opinions can provide insight into Autolus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Autolus Stock analysis
When running Autolus Therapeutics' price analysis, check to measure Autolus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Autolus Therapeutics is operating at the current time. Most of Autolus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Autolus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Autolus Therapeutics' price. Additionally, you may evaluate how the addition of Autolus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Stocks Directory Find actively traded stocks across global markets | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Autolus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.20) | Revenue Per Share 0.01 | Quarterly Revenue Growth (1.00) | Return On Assets (0.25) | Return On Equity (1.02) |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.